Resilience is a private company operating at the intersection of advanced biomanufacturing and cyber risk solutions, and this is a weekly summary of notable news about the firm. Over the past week, the company highlighted its growing role in next-generation therapeutic manufacturing while also releasing fresh data-driven insights into cybersecurity risks facing industrial clients.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Resilience emphasized its participation as a supporting partner and exhibitor at MassBio’s R&D Reimagined: Advanced Modalities conference in Boston on May 11. The company also plans to maintain a presence on the floor at the TIDES meeting and align its outreach with other major events such as ASGCT.
Across these industry gatherings, Resilience showcased capabilities in development, manufacturing, and sterile injectable operations, including prefilled syringes and vial-based fill-finish for complex biologics. The firm framed these offerings within a “right-first-time” operational culture aimed at technically complex, higher-value segments of the contract development and manufacturing space.
By deepening engagement with biotech and pharma R&D leaders focused on cell and gene therapies, RNA-based treatments, and other advanced platforms, Resilience is working to expand its pipeline of advanced-modality programs. Strengthened visibility and client relationships could support future contract manufacturing wins and improved capacity utilization in its biomanufacturing network.
In a separate development, Resilience published a report titled “The State of Cybersecurity in Manufacturing,” drawing on proprietary insurance claims data from its industrial portfolio. The analysis found that ransomware accounts for only 12% of incident volume but more than 90% of total incurred losses, underscoring the outsized financial impact of a small subset of attacks.
A single BlackCat ransomware incident linked to misconfigured multi-factor authentication emerged as the costliest case, with MFA failures representing roughly 26% of portfolio losses. The report highlighted mitigations such as auditing MFA deployments, tightening vulnerability management for internet-facing systems, and strengthening controls over financial transfers.
Resilience also recommended extending security requirements to critical vendors and supply chain partners to reduce systemic exposure across industrial ecosystems. Leadership, including CEO Vishaal “V8” Hariprasad and Risk Operations Center head Jud Dressler, emphasized that these measures are relatively straightforward yet provide substantial risk reduction.
By pairing cyber insurance with software and expert services, Resilience aims to position itself as a data-driven risk partner for large and mid-market organizations in the U.S., U.K., Canada, and Europe. Overall, the week underscored the company’s dual focus on scaling its advanced biomanufacturing footprint and sharpening its cyber risk capabilities, which together may enhance its competitive profile over the long term.